GB2538216A - Method of screening candidate biochemical entities targeting a target biochemical entity - Google Patents

Method of screening candidate biochemical entities targeting a target biochemical entity Download PDF

Info

Publication number
GB2538216A
GB2538216A GB1422724.3A GB201422724A GB2538216A GB 2538216 A GB2538216 A GB 2538216A GB 201422724 A GB201422724 A GB 201422724A GB 2538216 A GB2538216 A GB 2538216A
Authority
GB
United Kingdom
Prior art keywords
target
candidate
biochemical
signal
target biomolecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1422724.3A
Other languages
English (en)
Inventor
Salafsky Joshua
Benton Moree Carl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BlueLight Therapeutics Inc
Original Assignee
Biodesy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesy Inc filed Critical Biodesy Inc
Publication of GB2538216A publication Critical patent/GB2538216A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
GB1422724.3A 2013-06-13 2014-06-13 Method of screening candidate biochemical entities targeting a target biochemical entity Withdrawn GB2538216A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361834782P 2013-06-13 2013-06-13
PCT/US2014/042428 WO2014201435A1 (en) 2013-06-13 2014-06-13 Method of screening candidate biochemical entities targeting a target biochemical entity

Publications (1)

Publication Number Publication Date
GB2538216A true GB2538216A (en) 2016-11-16

Family

ID=52022828

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1422724.3A Withdrawn GB2538216A (en) 2013-06-13 2014-06-13 Method of screening candidate biochemical entities targeting a target biochemical entity

Country Status (6)

Country Link
US (1) US20150330990A1 (enExample)
EP (1) EP3008465B1 (enExample)
JP (2) JP6518656B2 (enExample)
CN (1) CN105659087B (enExample)
GB (1) GB2538216A (enExample)
WO (1) WO2014201435A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10672502B2 (en) 2015-04-02 2020-06-02 Biodesy, Inc. Methods for determining protein structure using a surface-selective nonlinear optical technique
GB2531213B (en) * 2014-06-30 2020-09-16 Biodesy Inc Systems and methods for high throughput analysis of conformation in biological entities
US11486881B2 (en) 2016-05-09 2022-11-01 Quanta Therapeutics, Inc. Methods and devices for detection of peripheral membrane protein interactions using nonlinear optical techniques

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
CA2831136A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
US9395358B2 (en) 2012-02-05 2016-07-19 Biodesy, Inc. Methods for detecting allosteric modulators of protein
US20130288271A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of protein
WO2013115867A1 (en) 2012-02-05 2013-08-08 Biodesy, Llc Methods for identifying modulators of ras using nonlinear techniques
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017053567A1 (en) * 2015-09-22 2017-03-30 Delta Tm Technologies Designing customized protein-specific buffer systems
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
CN106650209B (zh) * 2016-09-30 2020-07-07 中车南京浦镇车辆有限公司 一种车辆应用实时信息确定可靠性增长趋势及参数的方法
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN106650317B (zh) * 2016-10-09 2019-04-16 南京双运生物技术有限公司 一种通过协同过滤公共数据库发现肿瘤潜在基因标靶的方法
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018195134A1 (en) * 2017-04-18 2018-10-25 X-Chem, Inc. Methods for identifying compounds
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
TW201900633A (zh) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 Kras之共價抑制劑
US10657525B2 (en) 2017-06-27 2020-05-19 Kasisto, Inc. Method and apparatus for determining expense category distance between transactions via transaction signatures
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US20230236170A1 (en) * 2019-10-15 2023-07-27 Jnana Therapeutics Inc. Reactive affinity probe-interaction discovery platform
CN112630444B (zh) * 2020-12-11 2024-05-24 深圳碳云智肽药物科技有限公司 基于靶点蛋白的多肽筛选方法
CN113963745A (zh) * 2021-12-07 2022-01-21 国际竹藤中心 一种构建植物发育分子调控网络的方法及其应用
CN114317669A (zh) * 2022-01-04 2022-04-12 北京大学 一种基于细胞内蛋白激酶c激活状态筛选药物的方法及高通量筛选装置
WO2024129721A1 (en) * 2022-12-13 2024-06-20 Lafond David Systems and methods to predict biological receptor signal response

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107472A1 (en) * 2001-07-16 2005-05-19 The University Court Of The University Of Aberdeen Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
US20100068144A1 (en) * 2008-08-04 2010-03-18 Salafsky Joshua S Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US20100120164A1 (en) * 2002-01-24 2010-05-13 Biodesy, Llc Method using a nonlinear optical technique for detection of interactions involving a conformational change
WO2012129347A1 (en) * 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
US20130108549A1 (en) * 2006-07-28 2013-05-02 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505798A (ja) * 1996-02-01 2000-05-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド コルチコトロピン放出因子の内因性レベルを上昇させる方法
CA2414572A1 (en) * 2000-07-12 2002-01-17 Karo Bio Usa, Inc. Method of identifying conformation-sensitive binding peptides and uses thereof
US20020094528A1 (en) * 2000-11-29 2002-07-18 Salafsky Joshua S. Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interations
US20030129649A1 (en) * 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP1637885A1 (en) 2004-09-16 2006-03-22 Vivalis Method of screening by using conformation sensitive peptides
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
US20070238184A1 (en) * 2005-06-16 2007-10-11 The Regents Of The University Of California Amyloid beta protein channel structure and uses thereof in identifying potential drug molecules for neurodegenerative diseases
US20090010894A1 (en) * 2005-12-23 2009-01-08 The Parkinson's Institute Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
EP2326728A1 (en) * 2008-07-24 2011-06-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Fluorescently or spin-labeled kinases for rapid screening and identification of novel kinase inhibitor scaffolds
WO2010031185A1 (en) * 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
CN106290917B (zh) * 2012-04-25 2020-06-05 比奥德赛公司 用于检测蛋白质的变构调节剂的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107472A1 (en) * 2001-07-16 2005-05-19 The University Court Of The University Of Aberdeen Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
US20100120164A1 (en) * 2002-01-24 2010-05-13 Biodesy, Llc Method using a nonlinear optical technique for detection of interactions involving a conformational change
US20130108549A1 (en) * 2006-07-28 2013-05-02 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
US20100068144A1 (en) * 2008-08-04 2010-03-18 Salafsky Joshua S Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2012129347A1 (en) * 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531213B (en) * 2014-06-30 2020-09-16 Biodesy Inc Systems and methods for high throughput analysis of conformation in biological entities
US10672502B2 (en) 2015-04-02 2020-06-02 Biodesy, Inc. Methods for determining protein structure using a surface-selective nonlinear optical technique
US11486881B2 (en) 2016-05-09 2022-11-01 Quanta Therapeutics, Inc. Methods and devices for detection of peripheral membrane protein interactions using nonlinear optical techniques

Also Published As

Publication number Publication date
EP3008465A4 (en) 2017-02-15
JP2016527486A (ja) 2016-09-08
CN105659087B (zh) 2019-09-17
JP6518656B2 (ja) 2019-05-22
WO2014201435A8 (en) 2016-04-28
CN105659087A (zh) 2016-06-08
WO2014201435A1 (en) 2014-12-18
EP3008465A1 (en) 2016-04-20
JP2019135498A (ja) 2019-08-15
EP3008465B1 (en) 2019-08-07
US20150330990A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
GB2538216A (en) Method of screening candidate biochemical entities targeting a target biochemical entity
AR120262A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso
EA201890611A1 (ru) Библиотеки модульных полипептидов и способы их получения и применения
WO2017040930A3 (en) Biomarkers predictive of cytokine release syndrome
MX369149B (es) Construcciones de anticuerpos para cdh19 y cd3.
WO2018076024A3 (en) Methods for screening b cell lymphocytes
EP3606507A4 (en) SEROLOGICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG CANCER
CO6781536A2 (es) Agonistas de fgfr1 y sus métodos de uso
AR089825A1 (es) Metodo para determinar la ubicacion, tamaño y condiciones in situ en un yacimiento de hidrocarburos con ecologia, geoquimica y grupos de biomarcadores
MX2022013567A (es) Amplificacion de se?al en ensayos de compa?ero de union especifico de plasmones.
MX2016004865A (es) Metodo y dispositivo para analizar relacion social.
EP3538893A4 (en) PROCESSES FOR IDENTIFYING CANDIDATE BIOMARKERS
NZ629555A (en) Monocyte biomarkers for cancer detection
EP3647788A4 (en) BIOMARKER FOR THE DETECTION OF COLORECTAL CANCER
CY1124817T1 (el) Μεθοδος για την αναλυση γλυκοζαμινογλυκανων, ηπαρινων καi των παραγωγων τους με πυρηνικο μαγνητικο συντονισμο
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
HK1220253A1 (zh) 诊断前列腺癌症的方法
NZ710422A (en) Protein combination-based fv library, and preparation method therefor
EP3894861C0 (en) DETECTION OF BIOMARKERS FOR NON-SMALL CELL LUNG CANCER
EP3641815A4 (en) Fc-ScFv HYBRID ANTIBODY FORMAT ASYMMETRICAL HETERODIMER OF ACTIVATION AND INVOLVING T-LYMPHOCYTES DEPENDING ON TARGET CELLS FOR CARCINOTHERAPY
EP4428251A3 (en) Methods of detecting prostate cancer
WO2011100752A3 (en) Methods and materials for assessing rna expression
CA3018125C (en) SUBCELLULAR LOCALIZATION OF TARGET ANALYTES
MX363679B (es) Metodo para diagnosticar cancer.
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)